C-Q13OLeucadia Therapeutics
outpatient treatment, diagnostics, CT scan
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Q13O
C-Q13OC-Q13Ooutpatient treatment, diagnostics, CT scan
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Leucadia presented Alzheimer's disease as a condition driven by impaired clearance of toxic metabolites from the brain, especially when aging-related blockage develops at the cribriform plate. Its stated view was that this upstream drainage failure damages nearby brain regions and that restoring the brain's natural outflow pathway could stop, slow, or potentially reverse the disease process.
SourceLeucadia Therapeutics states that it is determined to end Alzheimer's disease and presents Arethusta as a first-in-class treatment for mild cognitive impairment associated with Alzheimer's disease. The company also expresses the view that Alzheimer's causes a kind of living loss for families and that new clinical and scientific approaches can address the disease earlier and more effectively.
SourceLeucadia Therapeutics presents itself as a company determined to end or erase Alzheimer's disease, framing the condition as an ongoing personal loss and asserting that it has a novel approach centered on Arethusta®, which it describes as a first-in-class treatment for mild cognitive impairment associated with Alzheimer's disease.
SourceLeucadia Therapeutics states that it is working to erase and end Alzheimer's disease, describing a novel approach centered on Arethusta®, which it presents as a first-in-class treatment for mild cognitive impairment associated with Alzheimer's disease.
Source